Six poster presentations include new analyses from Phase 2 STRIVE
clinical trial of rezafungin
Four oral presentations include first scientific presentation of
new data highlighting the potential of its Cloudbreak antiviral
conjugates (AVCs) for influenza
SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced a total of 10 upcoming presentations summarizing data on the
company’s lead antifungal rezafungin and its Cloudbreak antiviral
program at the 29th European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID). The company and its collaborators will
deliver four oral and six poster presentations at the meeting being held
in Amsterdam, Netherlands from April 13 to 16, 2019.
“The data to be presented at ECCMID will add to the growing body of
evidence demonstrating the potential for improved efficacy and safety of
rezafungin over current standard of care for the treatment of severe,
invasive infections, and as a prophylactic agent in high-risk patients,”
said Jeffrey Stein, Ph.D., president and chief executive officer of
Cidara. “We also look forward to sharing the first scientific
presentation of new data that highlight the potential of our Cloudbreak
antiviral conjugates (AVCs) for influenza. Our AVCs offer a
fundamentally novel approach designed to provide seasonal protection
from influenza, including those strains not covered by seasonal
vaccines. Because of their unique dual mechanism of action, our AVCs are
also, unlike vaccines, expected to protect patients with compromised
immune systems. Additionally, our AVCs could potentially be used to
treat patients suffering from severe influenza, beyond the limited
treatment window offered by currently approved therapies.”
ECCMID convenes leading experts from around the world to present and
discuss the latest research findings in infectious diseases, infection
control and clinical microbiology. Details of the 10 rezafungin and
Cloudbreak presentations are as follows:
Oral Presentations
Title: EUCAST susceptibility testing of rezafungin: MIC data for
contemporary Danish clinical yeast isolates
Presenter: K.M.
Jørgensen
Date and time: Saturday, April 13, 10:00 a.m. – 12:00
p.m. CET
Presentation time: 11:36 – 11:46 a.m. CET
Location:
Hall H
Oral Session: Issues in antifungal treatment
Title: Rezafungin PK/PD in a mouse model of Pneumocystis pneumonia
Presenter:
S. Flanagan
Date and time: Saturday, April 13, 2:45 – 3:45 p.m. CET
Presentation
time: 3:21 – 3:31 p.m. CET
Location: Hall N
Oral Session:
Novel approaches to fungal diseases
Title: Rezafungin is more effective than micafungin in treating of
FKS-mutant Candida glabrata intra-abdominal candidiasis
Presenter:
M-H. Nguyen
Date and time: Monday, April 15, 11:00 a.m. – 12:00
p.m. CET
Presentation time: 11:48 – 11:53 a.m. CET
Location:
Arena 2
Oral Session: Antifungals: novel drugs, novel dosing?
Title: Cloudbreak: a novel approach for the treatment and prevention of
influenza virus
Presenter: L. Tari
Date and time: Monday,
April 15, 1:30 – 3:30 p.m. CET
Presentation time: 2:18 – 2:28 p.m.
CET
Location: Hall M
Oral Session: New therapeutic strategies
in viral infections
Poster Presentations
Title: Phase II STRIVE clinical trial of rezafungin for the treatment of
candidemia and/or invasive candidiasis: results stratified by baseline
renal function
Presenter: S. Flanagan
Date and time: Saturday,
April 13, 3:30 – 4:30 p.m. CET
Location: Paper Poster Area
Poster
Session: Clinical pharmacokinetics, treatment strategies and prescribing
of antifungals
Title: Absorption, distribution and excretion of rezafungin after
single-dose intravenous administration in rats and monkeys
Presenter:
S. Flanagan
Date and time: Saturday, April 13, 3:30 – 4:30 p.m. CET
Location:
Paper Poster Area
Poster Session: Clinical pharmacokinetics,
treatment strategies and prescribing of antifungals
Title: Novel Cloudbreak bifunctional molecule protects against
Acinetobacter pneumonia
Presenter: A. Ibrahim
Date and time:
Monday, April 15, 1:30 – 2:30 p.m. CET
Location: Paper Poster Area
Poster
Session: In vitro activity of investigational antibacterial agents
Title: Outcomes in Europe from the STRIVE clinical trial of rezafungin
treatment of candidemia and/or invasive candidiasis
Presenter: T.
Sandison
Date and time: Tuesday, April 16, 12:30 – 1:30 p.m. CET
Location:
Paper Poster Area
Poster Session: Virulence and outcomes of fungal
infections
Title: EUCAST reference testing of rezafungin susceptibility: impact of
choice of plastic plates
Presenter: M. Arendrup
Date and time:
Tuesday, April 16, 12:30 – 1:30 p.m. CET
Location: Paper Poster Area
Poster
Session: Antifungal susceptibility and resistance in yeast and molds
from around the world
Title: Activity of rezafungin against common and rare Candida species in
vitro
Presenter: L. Majoros
Date and time: Tuesday, April
16, 12:30 – 1:30 p.m. CET
Location: Paper Poster Area
Poster
Session: Antifungal susceptibility and resistance in yeast and molds
from around the world
The abstracts can be accessed through the ECCMID website: www.eccmid.org.
Following the meeting, the presentation slides and posters will be
available on the Cidara website: www.cidara.com.
About Invasive Fungal Infections
Invasive fungal infections (IFIs) represent a serious global health
threat, resulting in more than 1.5 million deaths annually and mortality
rates ranging from 15 to 65 percent. These infections are especially
relevant for patients whose immune systems have been compromised, such
as patients undergoing organ or blood and marrow transplantation or
chemotherapy, including patients with hematologic malignancies. Of the
most significant IFIs, approximately 90 percent of related deaths are
primarily caused by Candida, Aspergillus, and Pneumocystis.
Candida species are most common in hospital-acquired infections,
while Aspergillus species are predominant in patients with
weakened immune systems or lung diseases. Pneumocystis infections
also commonly afflict immunocompromised patients.
About Influenza Virus
Influenza, or flu, is a respiratory infection caused by influenza
viruses. The flu virus can cause mild to severe illness, and at times
can lead to death. Young children, the elderly (over 65 years of age),
pregnant women and immunocompromised patients are more prone to
infection, but even healthy people are at risk of infection with
seasonal flu. While influenza vaccines are critical to global health,
they do not provide adequate protection year to year. The U.S. Center
for Disease Control and Prevention (CDC) estimates that as many as
646,000 people may die from influenza each year worldwide.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on the
discovery, development and commercialization of novel anti-infectives
that have the potential to transform the standard of care and save or
improve patients’ lives. Cidara is currently advancing its novel
echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical
trial, for the treatment of candidemia and invasive candidiasis and
continues to discuss with regulatory authorities its plans for the
design and the initiation of a second Phase 3 trial in the prophylaxis
of invasive fungal infections in patients undergoing allogeneic blood
and marrow transplantation. Rezafungin is the only once-weekly product
candidate in development for the treatment and prevention of
life-threatening invasive fungal infections. Cidara also is leveraging
its proprietary Cloudbreak® platform to develop antiviral
conjugates (AVCs) for serious infections, including further
investigation of the high potency and long half-life observed in its
AVCs for influenza. The Cloudbreak platform is designed to discover
compounds that both directly kill pathogens and direct a patient’s
immune system to attack and eliminate pathogens. Cidara is headquartered
in San Diego, California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, the potential for rezafungin to successfully treat or prevent
invasive fungal infections and represent an improvement over current
approaches, the potential for rezafungin in high-risk patient
populations and Cidara’s ability to successfully develop rezafungin.
Such statements also include, but are not limited to, statements
regarding the potential for Cidara’s AVCs to treat and prevent influenza
and represent an improvement over current vaccines, the efficacy of
Cidara’s AVCs in patients with compromised immune systems, and the
potential for Cidara’s AVCs to expand the treatment window and represent
an improvement over current therapies. Risks that contribute to the
uncertain nature of the forward-looking statements include: the success
and timing of Cidara’s preclinical studies and clinical trials;
regulatory developments in the United States and foreign countries;
changes in Cidara’s plans to develop and commercialize its product
candidates; Cidara’s ability to obtain additional financing; Cidara’s
ability to obtain and maintain intellectual property protection for its
product candidates; and the loss of key scientific or management
personnel. These and other risks and uncertainties are described more
fully in Cidara’s Form 10-K most recently filed with the United States
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which they
were made. Cidara undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the date on
which they were made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190326005154/en/
INVESTOR CONTACT:
Robert H. Uhl
Westwicke Partners, LLC
Managing
Director
(858) 356-5932
robert.uhl@westwicke.com
MEDIA CONTACT:
Andrea Cohen
Sam Brown Inc.
(917)
209-7163
andreacohen@sambrown.com
